We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Blueprint Medicines Corp (BPMC) USD0.001

Sell:$102.21 Buy:$102.29 Change: $1.33 (1.32%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Change: $1.33 (1.32%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
Change: $1.33 (1.32%)
Market closed |  Prices as at close on 22 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company is focused on crafting drug candidates that provide clinical responses to patients without adequate treatment options. Its lead medicines are AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib). Avapritinib is used for the treatment of systemic mastocytosis (SM), a rare hematologic disorder that causes an overproduction of mast cells and the accumulation of mast cells in the bone marrow and other organs. It is also commercializing avapritinib for the treatment of patients with PDGFRA exon 18 mutant gastrointestinal stromal tumors (GIST). The Company is developing and commercializing pralsetinib for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), and for the treatment of RET-altered thyroid carcinoma, including medullary thyroid carcinoma (MTC).

Contact details

45 Sidney St
United States
+1 (617) 3747580

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$5.99 billion
Shares in issue:
58.57 million
United States
US dollar

Key personnel

  • Jeffrey Albers
    Chairman of the Board, President, Chief Executive Officer
  • Michael Landsittel
    Chief Financial Officer
  • Fouad Namouni
    President - Research and Development
  • Kathryn Haviland
    Chief Operating Officer
  • Debra Durso-Bumpus
    Chief People Officer
  • Anthony Boral
    Executive Vice President - Clinical Development
  • Christopher Murray
    Senior Vice President - Technical Operations
  • Percy Carter
    Chief Scientific Officer
  • Tracey McCain
    Chief Legal and Compliance Officer
  • Ariel Hurley
    Vice President - Finance, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.